Brown, Lisle/Cummings’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$91.1K Sell
1,165
-164
-12% -$13.2K 0.02% 315
2026
Q1
$115K Buy
1,329
+92
+7% +$8.81K 0.03% 273
2025
Q4
$119K Sell
1,237
-133
-10% -$12.9K 0.03% 262
2025
Q3
$130K Sell
1,370
-6
-0.4% -$552 0.03% 254
2025
Q2
$120K Sell
1,376
-250
-15% -$21.2K 0.03% 260
2025
Q1
$146K Buy
1,626
+139
+9% +$12.4K 0.04% 236
2024
Q4
$119K Buy
1,487
+202
+16% +$17.5K 0.04% 249
2024
Q3
$116K Hold
1,285
0.04% 253
2024
Q2
$101K Sell
1,285
-100
-7% -$8.2K 0.03% 257
2024
Q1
$121K Hold
1,385
0.04% 233
2023
Q4
$114K Buy
1,385
+250
+22% +$19.1K 0.04% 230
2023
Q3
$88.9K Hold
1,135
0.04% 236
2023
Q2
$100K Buy
1,135
+323
+40% +$27.8K 0.04% 228
2023
Q1
$65.5K Hold
812
0.03% 254
2022
Q4
$63.1K Buy
812
+82
+11% +$6.65K 0.03% 248
2022
Q3
$58.9K Hold
730
0.03% 242
2022
Q2
$65.5K Hold
730
0.04% 234
2022
Q1
$81K Hold
730
0.04% 227
2021
Q4
$75.5K Buy
+730
New +$84.5K 0.04% 232

Other funds holding MDT

Brown, Lisle/Cummings's MDT Position: Q2 2026 in Review

Brown, Lisle/Cummings reduced its Medtronic (MDT) stake by 12% in Q2 2026, selling an estimated $13.2K and leaving 1,165 shares worth $91.1K. The position accounts for 0.02% of the portfolio, ranked #315.

Brown, Lisle/Cummings first reported a position in MDT in Q4 2021 and has held it in 19 quarters since. The position peaked at $146K in Q1 2025. 2,134 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Brown, Lisle/Cummings held 1,165 shares of Medtronic worth $91.1K as of Q2 2026.
  • Brown, Lisle/Cummings sold 164 Medtronic shares in Q2 2026, an estimated $13.2K.
  • Medtronic made up 0.02% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #315 holding.
  • Brown, Lisle/Cummings first reported a position in Medtronic in Q4 2021 and has held it in 19 quarters since.
  • Brown, Lisle/Cummings's Medtronic position peaked at $146K in Q1 2025.
  • 2,134 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.